Ginecología
Joan Brunet Programa de Cáncer de Programa Cáncer Hereditario, ICO Servicio Servicio de Oncología Médica, ICO Girona Criterios y Cómo Gestionarlo. Unidades Unidades Gestionarlo. y Cómo Criterios Qué Cáncer Ginecológico vs Unidades Ginecológico Cáncer
Information
interés de
Disclosure
conflictos
tengo
Grant support: support: Grant Other: Stock Ownership: Stock Funding: Research Speaking: Employment: Employment: Role: Advisoryor Consultant No
Outline
Quién debe indicar el estudio genético Una propuesta Cómo lo Cómo estamos gestionando Resultados de la gestión Quienes Quienes somos
BDL Gi -
-
Germans Dr. Josep Dr.
UCG
UCG
Universitari Universitari
Granollers Vic
i Pujol
Badalona Coloma de Gramenet Sta. Blanes Calella Figueres Olot Palamós Girona Caterina, Santa Mataró UCF UCF UCF
• • • • ICO BADALONA ICO Hospital Trias ICO GIRONA ICO Hospital Trueta • • • • • • •
UDM
Bellvitge
de de
BARCELONA
- Reynals
Penedès Ribes
del
de de Llobregat Broggi
Universitari
Boi de Pere Manresa
Hereditary Cancer Program Cancer Hereditary Igualada Martorell Sant Sant Viladecans Vilafranca Moisès UCF
• • • • • • • • ICO L’HOSPITALET ICO i Duran Hospital Hospital
L’H - UCG
BDL Gi -
-
Germans Dr. Josep Dr.
UCG
UCG
Universitari Universitari
Granollers Vic
i Pujol
Badalona Coloma de Gramenet Sta. Blanes Calella Figueres Olot Palamós Girona Caterina, Santa Mataró UCF UCF UCF
• • • • ICO BADALONA ICO Hospital Trias ICO GIRONA ICO Hospital Trueta • • • • • • •
UDM
Bellvitge
de de
BARCELONA
- Reynals
Penedès Ribes
del
de de Llobregat Broggi
Universitari
Boi de Pere Manresa
Hereditary Cancer Program Cancer Hereditary Igualada Martorell Sant Sant Viladecans Vilafranca Moisès UCF
• • • • • • • • ICO L’HOSPITALET ICO i Duran Hospital Hospital
L’H - UCG
BDL Gi -
-
Germans Dr. Josep Dr.
UCG
UCG
Universitari Universitari
Granollers Vic
i Pujol
Badalona Coloma de Gramenet Sta. Blanes Calella Figueres Olot Palamós Girona Caterina, Santa Mataró UCF UCF UCF
• • • • ICO BADALONA ICO Hospital Trias ICO GIRONA ICO Hospital Trueta • • • • • • •
UDM
Bellvitge
de de
BARCELONA
- Reynals
Penedès Ribes
del
de de Llobregat Broggi
Universitari
Boi de Pere Manresa
Hereditary Cancer Program Cancer Hereditary Igualada Martorell Sant Sant Viladecans Vilafranca Moisès UCF
• • • • • • • • ICO L’HOSPITALET ICO i Duran Hospital Hospital
L’H - UCG 50% of Catalonia population 50% of Catalonia
LDM -
UCG - , y referentes TFGT
- UCG’s nálisis nálisis de resultados a
: 2014 problema
Cómo lo hemos gestionado: SOM lo Cómo hemos gestionado: Definición Definición de indicadores, planificación de Acuerdo de Acuerdo despliegue progresivo en los casos en seguimiento: prioridad a los casos nuevos y a las pacientes con recidiva VCF con participación con participación VCF de oncólogos referentes en tumores ginecológicos de los centros ICO, referentes laboratorio Discusión Discusión y adaptación funciones consejeros genéticos Consenso de indicaciones y circuitos (estándar vs exprés) Propuesta Propuesta +/ de protocolo de indicaciones: RA Definición de circuitos exprés: asistencial y laboratorio Identificación Identificación del
UCG’s
network -
Acciones de gestión en paralelo desde las las desde paralelo en gestión de Acciones test: mayor implicación test: mayor implicación del consejero genético - circuito circuito exprés y de los tiempos Post Revisar las indicaciones exprés, no todas son exprés! Análisis semestral/anual: cumplimiento en los de criterios uso del servicios servicios hospitalarios, telemedicina Más competencias a las UCF integradas en el PCH Gestión Gestión de la demanda general: reducir número el de primeras visitas que no son de alto riesgo: sesiones con atención y primaria
indicación Estándard terapéutica No
Asesoramiento * de
10 días + Test <5 semanas a fecha informe semanas <5 Test 10 +días
- ovario
Cáncer
CG en C. Ovario: Procedimiento ICO Procedimiento Ovario: en C. CG Express** Indicación terapéutica Asesoramiento *Todos menos mucinosos 0 **Pre test menos mucinosos *Todos
*
Otros Estudio Genético Estándard
Hereditario . *En revisión por implantación implantación revisión por *En panel
Sd
CMOH
Genético
.
Express Express Asesoramiento Estudio Endometr
HGSOC/F/CP HG
Sd No
Hereditario
Clínico
Estudio Externo Genético Ensayo y LDM
UCG’s
Evolución actividad 1as Visitas actividad 1as Visitas Evolución y LDM
UCG’s
Evolución actividad 1as Visitas actividad 1as Visitas Evolución y LDM
UCG’s
Evolución actividad 1as Visitas actividad 1as Visitas Evolución
1/9 1/4 Mutación
39) 82) - -
(26 30 (55 75 Tiempo (días)* Tiempo
N 11 17 Indicaciones CO 1/1a 4/6 2015
* Tiempo entre extracción y fecha de informe resultado de informe de fecha y extracción entre Tiempo * Estándard Tipo Express
in in
with
result
become
could
presenting
. should
patients patients
risk understanding - geneticists
harm high
a full a full and
clinical for
with
without
services
prevention
tools
cancer
possible
collaboration Quién debe indicar estudio el indicar debe Quién
for
best
assessment
close , mainstream risk
of
provide
to
part opportunities
concerns
genetic
order cancer routine missed In Using
and
in in
including , cancer
supported
support
breast rather guidelines in in
but
educational
practices
recognized
restricted best
be
for
continuing exceed
not
or
meet
should processes welcome
that and
.
Quién debe indicar estudio el indicar debe Quién would
services
they
practices
elements
counseling that
.
test test . report appropriate
noted
necessary
They these . genetics … expanded genetics … the most
.
based - lasting the
members or
, generation guideline - family
counseling to
three their syndromes test test
a -
and pre
cancer
adherence for
of
patients
constructed
lack to
session
hereditary Few
This harm
,….. ,….. . …. separate a
direct Quién debe indicar estudio el indicar debe Quién result
testing alternative
in in
to variant result
scheduling
discussed of a ,
may
30 min prior
– 11 pedigree meaning practice sometimes ,
.,
but , e.g
( cancer
is
readily in in be
be
characteristics may counselors consent not
,… counseling
expertise
may genetic
with …..
and tumor genetic
appropriate
circumstances
certified clinical services cancer
provider
after
a
in in of
such ). by
board
. In testing
R.N.s not , training training counseling
are are
assessment
genetic locations conducted
who genetic
Quién debe indicar estudio el indicar debe Quién appropriate includes professionals
include
counseling geographic that
may
individuals
specialized all and practice received
- by in in ….
, and , process have a
is
advanced available provided who …. education genetics obtained
19 Annals of Oncology 2014: 25(suppl 4) 25(suppl2014:Annalsof Oncology
George A et al, et A George
Refer to Refer
Genetics required More discussion discussion More
appt
No mutation No
offered on request patient. *Genetic *Genetic patient. info sheet sheet (MSinfo IS2) to Clinician Clinician result gives &
mucinous OC diagnosed <65 years <65 diagnosed OC mucinous Mutation - *Genetics will will and*Genetics issue results. Report Consent obtained and scanned onto EPR onto scanned and obtained Consent lab formto sent request and(2xEDTA) Blood Genetics to notification EPR Information sheet (MS IS1) given to patient(MS IS1) givensheet Information discussed testing BRCA Non age any at cancer breast and OC notification to clinician clinician weeks. to by EPR within 8 notification patient. *Genetic *Genetic patient. appt 3. 4. 5. *ACTIONS by approved clinician by approved *ACTIONS 1. 2. • • NHS RMH patient with: RMH patient NHS Clinician Clinician result gives to letter sent sent 3 weeks after letter report issued report issued to Oncology
20
- BRCA
BRCA2 December 2013)December - and12 x
BRCA1
Annals of Oncology 2014: 25(suppl 4) 25(suppl2014:Annalsof Oncology
George A et al, et A George
were being offered testingbeingofferedwere appointmentGeneticsweekswithintheir with 4 and mutations patientsreceived All foundfamily helpingit usefultheirfor all 119 patientswere testedthe6 months (July in first 119 to testinginputprior patientsGenetics additionalNo requested mutation: a (17%) carriedpatients 820 x thosewith a mutation, Of12/20 of (60%) breasthadand/orOC history nofamily 1 hadonlybeen criteria, thethat referral mutation met Geneticscarriers currentOf testing offered thehadof 9 mutation animmediate carriers change in management dueto status were pleasedhave100% tono hadwould testing; patients have preferredreferral to to testingprior Genetics 98% non family; offor had their understoodthepatients implications results All forhad themselvesunderstoodtheand100% implications results carriers of carriers foundpatientsthe informationAll patient and sheethelpful understood why they • • • • • • • • • • Results
Refer to Refer
Genetics required More discussion discussion More
appt
No mutation No
offered on request patient. *Genetic *Genetic patient. info sheet sheet (MSinfo IS2) to Clinician Clinician result gives &
mucinous OC diagnosed <65 years <65 diagnosed OC mucinous Mutation - *Genetics will will and*Genetics issue results. Report Consent obtained and scanned onto EPR onto scanned and obtained Consent lab formto sent request and(2xEDTA) Blood Genetics to notification EPR Information sheet (MS IS1) given to patient(MS IS1) givensheet Information discussed testing BRCA Non age any at cancer breast and OC notification to clinician clinician weeks. to by EPR within 8 notification patient. *Genetic *Genetic patient. appt 3. 4. 5. *ACTIONS by approved clinician by approved *ACTIONS 1. 2. • • NHS RMH patient with: RMH patient NHS Clinician Clinician result gives to letter sent sent 3 weeks after letter report issued report issued to Oncology
<6 w <6 < 12 w 12 < Express Standard
Consent
10 d 10 - 0 assessment
Risk Informed
Cancer
TFGT Ovarian
<6 w <6 < 12 w 12 < Express Standard
Consent
* 10 d 10 - 0 assessment
Risk Informed
Cancer
TFGT
Ovarian CGU Genetic Counsellor CGU Genetic
* OGT Trained Physician or Nurse or Genetic Counsellor: coordinated with CGU with Genetic coordinated Counsellor: or Physician or Nurse Trained OGT *
,..
Mutation,VUS
risk
and and
Results uncertain mutation / Test Test No high
<6 w <6 mutation < 12 w 12 < Express Standard
No
Consent
* 10 d 10 - 0 assessment
Risk Informed
Cancer
TFGT
Ovarian CGU Genetic Counsellor CGU Genetic
* OGT Trained Physician or Nurse or Genetic Counsellor: coordinated with CGU with Genetic coordinated Counsellor: or Physician or Nurse Trained OGT *
,..
Mutation,VUS
risk
and and
Results uncertain
mutation / Test Test No high Team
Gynecology - <6 w <6 mutation < 12 w 12 < Express Standard
No Oncology
Consent
* 10 d 10 - 0 assessment
Risk Informed
Cancer
TFGT
Ovarian CGU Genetic Counsellor CGU Genetic
* OGT Trained Physician or Nurse or Genetic Counsellor: coordinated with CGU with Genetic coordinated Counsellor: or Physician or Nurse Trained OGT *
,..
Mutation,VUS
GCU risk
and and
Results uncertain
mutation / Test Test No high Team
Gynecology - <6 w <6 mutation < 12 w 12 < Express Standard
No Oncology
Consent
* 10 d 10 - GCU 0 assessment
Risk Informed
Cancer
TFGT
Ovarian CGU Genetic Counsellor CGU Genetic
* OGT Trained Physician or Nurse or Genetic Counsellor: coordinated with CGU with Genetic coordinated Counsellor: or Physician or Nurse Trained OGT *
messages
lab home -
apropiado ucg prevención prevención CO -
Take y
gine -
onco
screening
disciplinar disciplinar - genetic (temporal!) trans
asesoramiento asesoramiento genético y evaluación del riesgo única de Oportunidad Visión cooperativa Visión NO importa quien hace petición SÍ importa que haya un Las UCG Las UCG deben reorganizarse, revisar las funciones de sus miembros (médico, consejeros genéticos) y gestionar la demanda general para las asumir nuevas indicaciones urgentes o estándar. urgentes o estándar. Hay que definir circuitos TFGT preferentes para el Se deben deben Se diferenciar las indicaciones con finalidad terapéutica
Romeu collaborators
and
members
Program
: P. Barretina, M. Gil, B. Pardo, M. B. M. Pardo, Gil, Barretina, : P. Cancer team ICO ICO
Hereditary OncoGynae the to thanks
Special